Affiliations: First Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Laiko General Hospital, Athens 11527, Greece, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens 11528, Greece
Published online on:October 8, 2021https://doi.org/10.3892/ol.2021.13082
Recently, immunotherapy has shown promising results in solid tumors. To the best of our knowledge, this is the first systematic review of published literature synthesizing all the available data and evaluating both the efficacy and safety of pembrolizumab in endometrial cancer. The present study was performed in accordance with the PRISMA guidelines. Eligible articles were identified by searching the MEDLINE and ClinicalTrials.gov databases, using a predefined combination of the terms ‘endometrial cancer’ and ‘pembrolizumab’. Overall, nine articles incorporating data from 712 patients were eligible. Pembrolizumab was demonstrated to be an effective and safe therapeutic option for the management of advanced/metastatic endometrial cancer. Results of ongoing trials evaluating either pembrolizumab alone or in combination with other antineoplastic regimens are expected to confirm its efficacy in this setting of patients. Pembrolizumab appears to be both durable and robust in endometrial cancer. However, there is an emerging need for novel predictive biomarkers to guide clinical practice.
Something has gone wrong
HTTP Error 400
Well this is embarrassing. Something has gone wrong. Hopefully it is a transient error that will go away if you retry.
If the problem persists if you email our System Administrators letting them know what you were doing and telling them it was because:
Exception evaluating SpringEL expression: "dispArt?.images" (template: "article" - line 384, col 9)